Clasp Ther­a­peu­tics emerges with $150M based on work from Bert Vo­gel­stein, Drew Par­doll

Re­searchers at Johns Hop­kins Uni­ver­si­ty have launched an­oth­er biotech that builds on more than a decade of in­ves­ti­ga­tion that they hope will im­prove T cell en­gagers and lim­it their off-tu­mor tox­i­c­i­ties.

Bert Vo­gel­stein, who found­ed com­pa­nies like Thrive and Haystack On­col­o­gy, has been work­ing with Drew Par­doll for years on mu­ta­tion-as­so­ci­at­ed neoanti­gens, or MAN­As. They formed a biotech around the idea in 2020, nam­ing it Man­aT Bio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER